Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2930007

Clc1cccc(Cc2ccc(CN3CCCC3)c(Cl)c2)c1.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.57
LTA4H P09960 2/20 0.54
CYP2A13 Q16696 1/20 0.51
POLB P06746 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
CACNB4 O00305 1/20 0.47
CACNA1A O00555 1/20 0.47
CACNA1G O43497 1/20 0.47
CACNG3 O60359 1/20 0.47
CACNA1F O60840 1/20 0.47
CACNA1H O95180 1/20 0.47
CACNB3 P54284 1/20 0.47
CACNA2D1 P54289 1/20 0.47
CACNG7 P62955 1/20 0.47
CACNA1B Q00975 1/20 0.47
CACNA1D Q01668 1/20 0.47
CACNB1 Q02641 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL2923323 0.89 CYP2A13 (0.68) SIGMAR1CYP2A13KDM4EALDH1A1SMN1; SMN2
Ammonia Solution, Strong SCHEMBL2926473 0.87 LTA4H (0.64) SIGMAR1LTA4HPOLBKDM4EALDH1A1
SCHEMBL2930005 0.79 SIGMAR1 (0.49) SIGMAR1CYP2A13POLBKDM4EALDH1A1
SCHEMBL29447340 0.78 SIGMAR1 (0.79) SIGMAR1POLBKDM4EALDH1A1TDP1
SCHEMBL3169406 0.78 SIGMAR1 (0.79) SIGMAR1POLBKDM4EALDH1A1TDP1
SCHEMBL24508364 0.78 KDM4E (0.73) SIGMAR1CYP2A13POLBKDM4EALDH1A1
Ammonia Solution, Strong SCHEMBL2931430 0.77 SIGMAR1 (0.58) SIGMAR1LTA4HCYP2A13KDM4EALDH1A1
SCHEMBL5732659 0.77 SIGMAR1 (0.77) SIGMAR1POLBKDM4EALDH1A1TDP1
SCHEMBL1890670 0.77 SIGMAR1 (0.77) SIGMAR1POLBKDM4EALDH1A1TDP1
SCHEMBL30596611 0.77 KDM4E (0.71) SIGMAR1CYP2A13POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed
EP-2121616-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS Campiani, Giuseppe (IT) 2009-11-25 EP disclosed
WO-2008101891-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 SIGMAR1 2671/4885LTA4H 1402/4885CYP2A13 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.